Further studies would also be essential to determine the cut-off value of PON1 activity, predicting the risk of PCa recurrence after RT and the possible relation of PON1 concentration with the risk of recurrence, especially since such relations were reported for lung and breast cancers [11,14]. The gene discussed is PON1; the disease is posterior cortical atrophy.